UDP-glucuronosyl Transferase 1A6 (UGT1A6) Genotyping
UGT1A6 (UDP-glucuronosyl transferase 1A6) is a phase II drug metabolism enzyme transcribed by the UGT1A6 gene located at 2q37.1. UGT1A6 is primarily expressed in hepatocytes and is an important enzyme, involved in glucuronide conjugation of substances to render them water-soluble so that they can be easily excreted in the urine. Lipophilic molecules like steroid hormones, bilirubin, and lipophilic drugs require glucuronide conjugation for excretion. The UGT1A6 is also important in the excretion of xenobiotics and preventing their toxic accumulation.
UGT1A6 isoenzyme specifically conjugates phenolic compounds such as salicylates, acetaminophen, and anthracycline. Single-nucleotide polymorphisms (SNPs) in the UGT1A6 gene may result in diminished UGT1A6 transcription, deficient glucuronidation, and consequently poor excretion of these drugs. SNPs in the UGT1A6 gene are associated with valproate-induced weight gain in epilepsy patients. Likewise, these are also associated with cardiotoxicity upon administration of anthracycline drugs. By impairing the glucuronidation of toxic anthracycline metabolites. Individuals carrying the T-allele of variant rs17863783 in the UGT1A6 gene are at increased risk for these toxic effects and it is suggested that patients should be screened prior to the administration of these drugs. However, current consensus recommendations do not recommend genetic screening prior to initiating anthracycline therapy.
- Useful in predicting anthracycline-induced cardiotoxicity
- Aids in the selection of appropriate anti-cancer drugs
A positive result indicates the presence of variant rs17863783 T-allele in the UGT1A6 gene. The result is further interpreted as:
- Low risk: individuals with T/G allele. (Heterozygous)
- High risk: individuals with T/T allele. (Homozygous)
A negative result indicates the absence of variant rs17863783 T-allele in the UGT1A6 gene.
Negative (rs17863783 G/G indicates normal UGT1A6 enzyme functioning)
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unstable
- J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. [PMID: 15761113]
- Epilepsy Res. 2021 Nov;177:106786. [PMID: 34656038]
- Pharmacogenetics. 2004 Aug;14(8):487-99. [PMID: 15284531]
- Drug Metab Dispos. 2009 Aug;37(8):1726-32. [PMID: 19406951]
- Front Cardiovasc Med. 2022 Apr 21;9:867873. [PMID: 35528837]